MDR1-EXPRESSING CD4⁺ T CELLS WITH TH1.17 FEATURES RESIST TO NEOADJUVANT CHEMOTHERAPY AND ARE ASSOCIATED WITH BREAST CANCER CLINICAL RESPONSE.

ABSTRACT:

Background

Multidrug resistance-1 (MDR1) transporter limits the intracellular accumulation of chemotherapies (paclitaxel, anthracyclines) used in breast cancer (BC) treatment. In addition to tumor cells, MDR1 is expressed on immune cell subsets in which it confers chemoresistance. Among human T cells, MDR1 is expressed by most CD8⁺ T cells, and a subset of CD4⁺ T helper (Th) cells. Here we explored the expression, function and regulation of MDR1 on CD4⁺ T cells and investigated the role of this population in response to neoadjuvant chemotherapy (NAC) in BC.

Methods

Phenotypic and functional characteristics of MDR1⁺ CD4 Th cells were assessed on blood from healthy donors and patients with BC by flow cytometry. These features were ex

SUBMITTER: Di Roio A 

PROVIDER: S-EPMC10632904 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature